A Phase II Study of Pazopanib (GW786034 NSC# 737754) in Children Adolescents and Young Adults with Refractory Solid Tumors
-
- STATUS
- Not Recruiting
Summary
The purpose of this study is to find out what effects, good or bad, pazopanib (GW786034), National Service Center (NSC) # 737754, has on children, adolescents and young adults between 12 months and less than or equal to 18 years of age with relapsed or refractory rhabdomyosarcoma, non rhabdomyosarcomatous soft tissue sarcoma, Ewing sarcoma, relapsed or refractory osteosarcoma, neuroblastoma (measurable and/or evaluable), or hepatoblastoma.
Description
The purpose of this study is to test the safety of pazopanib in children, adolescents and young adults.
Details
| Condition | Refractory Solid Tumor |
|---|---|
| Age | 1years - 18years |
| Clinical Study Identifier | TX4397 |
| Last Modified on | 19 February 2024 |
Similar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.